#$BBIO +15.9%, #$BMRN -9.5% [BridgeBio's oral infigratinib outperforms BioMarin's injectable therapy in boosting growth for kids with achondroplasia, marking a major win in treating the genetic cause of dwarfism.] notreload.xyz/bridgebio-br...
BridgeBio's Breakthrough: Oral Drug Succeeds in Dwarfism Study
BridgeBio's oral infigratinib outperforms BioMarin's injectable therapy in boosting growth for kids with achondroplasia, marking a major win in treating the genetic cause of dwarfism.
notreload.xyz
February 12, 2026 at 1:10 PM
#$BBIO +15.9%, #$BMRN -9.5% [BridgeBio's oral infigratinib outperforms BioMarin's injectable therapy in boosting growth for kids with achondroplasia, marking a major win in treating the genetic cause of dwarfism.] notreload.xyz/bridgebio-br...
Who is Peter Dinklage?
I. Origins and Early Aspirations Peter Dinklage was born on June 11, 1969, in the Jersey Shore region of New Jersey. He grew up in Morristown, where his interest in performance first emerged. Born with achondroplasia, a form of dwarfism, Dinklage faced a world unprepared to…
I. Origins and Early Aspirations Peter Dinklage was born on June 11, 1969, in the Jersey Shore region of New Jersey. He grew up in Morristown, where his interest in performance first emerged. Born with achondroplasia, a form of dwarfism, Dinklage faced a world unprepared to…
Who is Peter Dinklage?
I. Origins and Early Aspirations Peter Dinklage was born on June 11, 1969, in the Jersey Shore region of New Jersey. He grew up in Morristown, where his interest in performance first emerged. Born with achondroplasia, a form of dwarfism, Dinklage faced a world unprepared to celebrate actors like him. Yet from an early age, he demonstrated an appetite for rich characters and deeply human storytelling.
theknowledgebase.net
February 11, 2026 at 4:20 PM
Who is Peter Dinklage?
I. Origins and Early Aspirations Peter Dinklage was born on June 11, 1969, in the Jersey Shore region of New Jersey. He grew up in Morristown, where his interest in performance first emerged. Born with achondroplasia, a form of dwarfism, Dinklage faced a world unprepared to…
I. Origins and Early Aspirations Peter Dinklage was born on June 11, 1969, in the Jersey Shore region of New Jersey. He grew up in Morristown, where his interest in performance first emerged. Born with achondroplasia, a form of dwarfism, Dinklage faced a world unprepared to…
Ready for prime time. Study shows vosoritide trial results are reproducible and favorable in a real-world setting bit.ly/3ZOedVj #achondroplasia #precisionmedicine #growth
February 11, 2026 at 12:26 AM
Ready for prime time. Study shows vosoritide trial results are reproducible and favorable in a real-world setting bit.ly/3ZOedVj #achondroplasia #precisionmedicine #growth
that being said passion is important. v'ehxshou is forcing me to stop being lazy and figure out how to draw muscuar bodies and achondroplasia proportions.
February 8, 2026 at 7:05 AM
that being said passion is important. v'ehxshou is forcing me to stop being lazy and figure out how to draw muscuar bodies and achondroplasia proportions.
🇺🇸 Life Insurance With Dwarfism & Achondroplasia 👉 bcli.link/Dwarfism - Ask Our Answer Bot a Question 👉 bcli.link/Bot - #LifeInsuranceWithDwarfism #LifeInsuranceWithAchondroplasia
January 27, 2026 at 2:34 PM
🇺🇸 Life Insurance With Dwarfism & Achondroplasia 👉 bcli.link/Dwarfism - Ask Our Answer Bot a Question 👉 bcli.link/Bot - #LifeInsuranceWithDwarfism #LifeInsuranceWithAchondroplasia
Case report describes a patient with a postzygotic FGFR3 p.Ser249Cys variant presenting with acanthosis nigricans, generalized epidermal nevus, and features of severe achondroplasia with developmental delay. ja.ma/49KgOW4
January 27, 2026 at 1:00 PM
Case report describes a patient with a postzygotic FGFR3 p.Ser249Cys variant presenting with acanthosis nigricans, generalized epidermal nevus, and features of severe achondroplasia with developmental delay. ja.ma/49KgOW4
ROPEL 3 is the moment.
Infigratinib (oral FGFR1–3 inhibitor) for achondroplasia: Phase 2 hinted growth gains; Phase 3 topline soon.
Readout triage: efficacy, safety, access.
Full outlook → future.xsbrt.com/OralInfigrat...
Infigratinib (oral FGFR1–3 inhibitor) for achondroplasia: Phase 2 hinted growth gains; Phase 3 topline soon.
Readout triage: efficacy, safety, access.
Full outlook → future.xsbrt.com/OralInfigrat...
FutureLens — Curated Forecasts, Odds & Timelines
Explore curated forecasts with evidence, scenario odds, and clear timelines.
future.xsbrt.com
January 25, 2026 at 3:23 PM
ROPEL 3 is the moment.
Infigratinib (oral FGFR1–3 inhibitor) for achondroplasia: Phase 2 hinted growth gains; Phase 3 topline soon.
Readout triage: efficacy, safety, access.
Full outlook → future.xsbrt.com/OralInfigrat...
Infigratinib (oral FGFR1–3 inhibitor) for achondroplasia: Phase 2 hinted growth gains; Phase 3 topline soon.
Readout triage: efficacy, safety, access.
Full outlook → future.xsbrt.com/OralInfigrat...
## Automated Skeletal Growth Prediction and Personalized Orthopedic Planning for Children with Achondroplasia Utilizing Multi-Modal Deep Learning and HyperScore Evaluation
**Abstract:** This paper details a novel system leveraging multi-modal deep learning and a HyperScore evaluation framework to…
**Abstract:** This paper details a novel system leveraging multi-modal deep learning and a HyperScore evaluation framework to…
## Automated Skeletal Growth Prediction and Personalized Orthopedic Planning for Children with Achondroplasia Utilizing Multi-Modal Deep Learning and HyperScore Evaluation
**Abstract:** This paper details a novel system leveraging multi-modal deep learning and a HyperScore evaluation framework to predict long-term skeletal growth trajectories in children diagnosed with achondroplasia (a low-stature dwarfism condition) and subsequently optimize orthopedic intervention planning. Current growth prediction methods are subjective and often inaccurate, hindering the effectiveness of surgical interventions and impacting long-term quality of life. Our system combines radiographic analysis (X-ray images), anthropometric measurements, genetic data, and lifestyle factors to create personalized growth models.
freederia.com
January 19, 2026 at 7:12 PM
## Automated Skeletal Growth Prediction and Personalized Orthopedic Planning for Children with Achondroplasia Utilizing Multi-Modal Deep Learning and HyperScore Evaluation
**Abstract:** This paper details a novel system leveraging multi-modal deep learning and a HyperScore evaluation framework to…
**Abstract:** This paper details a novel system leveraging multi-modal deep learning and a HyperScore evaluation framework to…
When you wake up with achondroplasia:
i’m in the mood to be disruptive today. good luck to you all.
January 17, 2026 at 12:51 PM
When you wake up with achondroplasia:
January 15, 2026 at 3:02 AM
Achondroplasia is the most common genetic skeletal dysplasia and primary cause of disproportionate short-limbed dwarfism.
Learn more: www.beyondachondroplasia.org/en/
You may be rare, but you're not alone!
#rareDisease #rareDiseaseAwareness
Learn more: www.beyondachondroplasia.org/en/
You may be rare, but you're not alone!
#rareDisease #rareDiseaseAwareness
January 14, 2026 at 3:04 PM
Achondroplasia is the most common genetic skeletal dysplasia and primary cause of disproportionate short-limbed dwarfism.
Learn more: www.beyondachondroplasia.org/en/
You may be rare, but you're not alone!
#rareDisease #rareDiseaseAwareness
Learn more: www.beyondachondroplasia.org/en/
You may be rare, but you're not alone!
#rareDisease #rareDiseaseAwareness
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
Follow Play Earnings CallPlay Earnings Call Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP…
Follow Play Earnings CallPlay Earnings Call Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP…
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
Follow Play Earnings CallPlay Earnings Call Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia January 8, 2026 4:30 PM EST Company Participants Scott Smith - CFO, Executive VP & Member of Executive BoardJan Mikkelsen - President, CEO, Member of Executive Board & Executive DirectorAimee Shu - Executive VP & Chief Medical Officer…
fintechguide24.com
January 9, 2026 at 3:58 AM
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
Follow Play Earnings CallPlay Earnings Call Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP…
Follow Play Earnings CallPlay Earnings Call Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP…
Exhibit B is Savulescu's silly "welfarist" definition of disability. Exhibit C is Jonathan Glover saying achondroplasia shouldn't be classified as a disability
January 9, 2026 at 1:13 AM
Exhibit B is Savulescu's silly "welfarist" definition of disability. Exhibit C is Jonathan Glover saying achondroplasia shouldn't be classified as a disability
#ASND Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
https://www.stocktitan.net/news/ASND/week-52-coach-trial-topline-results-confirm-consistent-and-durable-kh85nax9pcbe.html
https://www.stocktitan.net/news/ASND/week-52-coach-trial-topline-results-confirm-consistent-and-durable-kh85nax9pcbe.html
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
– Once-weekly TransCon ® CNP and TransCon ® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-percentile of average stature children – ACH height Z-score improvements indicated a tripling of
www.stocktitan.net
January 8, 2026 at 9:01 PM
#ASND Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
https://www.stocktitan.net/news/ASND/week-52-coach-trial-topline-results-confirm-consistent-and-durable-kh85nax9pcbe.html
https://www.stocktitan.net/news/ASND/week-52-coach-trial-topline-results-confirm-consistent-and-durable-kh85nax9pcbe.html
Once-weekly navepegritide increased growth velocity and improved skeletal alignment and quality of life in children with #achondroplasia, with a safety profile comparable to placebo. ja.ma/3Ny5aVg
January 8, 2026 at 1:00 PM
Once-weekly navepegritide increased growth velocity and improved skeletal alignment and quality of life in children with #achondroplasia, with a safety profile comparable to placebo. ja.ma/3Ny5aVg
Moving beyond monogenic disorders in clinical healthcare
https://www.europesays.com/ie/272822/
Although some genetic disorders, such as achondroplasia (related to the gene FGFR3), are caused by single genetic aberrations…
https://www.europesays.com/ie/272822/
Although some genetic disorders, such as achondroplasia (related to the gene FGFR3), are caused by single genetic aberrations…
Moving beyond monogenic disorders in clinical healthcare - Ireland
Although some genetic disorders, such as achondroplasia (related to the gene FGFR3), are caused by single genetic aberrations with near-complete penetrance,
www.europesays.com
January 7, 2026 at 9:00 PM
Moving beyond monogenic disorders in clinical healthcare
https://www.europesays.com/ie/272822/
Although some genetic disorders, such as achondroplasia (related to the gene FGFR3), are caused by single genetic aberrations…
https://www.europesays.com/ie/272822/
Although some genetic disorders, such as achondroplasia (related to the gene FGFR3), are caused by single genetic aberrations…
omg i love your style sm!! And he's so cool,,,
*I also have achondroplasia! So it's really cool to see ocs with the same condition :3
*I also have achondroplasia! So it's really cool to see ocs with the same condition :3
a close up of a cat standing next to a yellow bowl in a bathroom .
Alt: Cat jumping up and down with excitement
media.tenor.com
January 6, 2026 at 9:18 AM
omg i love your style sm!! And he's so cool,,,
*I also have achondroplasia! So it's really cool to see ocs with the same condition :3
*I also have achondroplasia! So it's really cool to see ocs with the same condition :3
Guys, they gave sheep achondroplasia.
January 5, 2026 at 11:46 AM
Guys, they gave sheep achondroplasia.
This is a deep cut, but IMO, the fact that Puck from Alpha Flight's back story was changed to "he used to be really tall but then a demon made him short" is one of the worst examples. Puck had already previously said he had the genetic condition "achondroplasia," so it was a horrible retcon.
January 4, 2026 at 11:21 PM
This is a deep cut, but IMO, the fact that Puck from Alpha Flight's back story was changed to "he used to be really tall but then a demon made him short" is one of the worst examples. Puck had already previously said he had the genetic condition "achondroplasia," so it was a horrible retcon.
Humeri are typically only done in cases of disproportional upper limbs, as can be seen in achondroplasia, where the upper parts of the limb (humerus and femur) are shorter than the lower parts.
December 30, 2025 at 2:28 PM
Humeri are typically only done in cases of disproportional upper limbs, as can be seen in achondroplasia, where the upper parts of the limb (humerus and femur) are shorter than the lower parts.
December 23, 2025 at 10:35 PM
December 23, 2025 at 2:28 AM
I had an aunt with achondroplasia. She hated it. She was still a religious person, but if science had offered her a way to have a normal body, she would have taken it.
December 22, 2025 at 9:10 AM
I had an aunt with achondroplasia. She hated it. She was still a religious person, but if science had offered her a way to have a normal body, she would have taken it.
December 21, 2025 at 11:19 PM